A Single Ascending Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-7252 in Healthy Subjects

Trial Profile

A Single Ascending Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-7252 in Healthy Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs MK-7252 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 11 Apr 2018 Planned End Date changed from 10 Apr 2018 to 23 Apr 2018.
    • 11 Apr 2018 Planned primary completion date changed from 10 Apr 2018 to 23 Apr 2018.
    • 05 Mar 2018 The treatment table has been amended to reduce the dosage of MK-725. Patients now receive all the treatment in Fasted state. No fed state.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top